Future studies further elucidating mechanisms of action and function of the different ERR subtypes in ovarian cancer as well as in vivo approaches to test the applicability of ERR modulators in treatment of this cancer entity are necessary. The gene discussed is SLC7A1; the disease is ovarian cancer.